| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1063 | 2018 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 421 | 2017 |
| Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial HM Kantarjian, GJ Roboz, PL Kropf, KWL Yee, CL O'Connell, R Tibes, ... The Lancet Oncology 18 (10), 1317-1326, 2017 | 169 | 2017 |
| DNA hypomethylating drugs in cancer therapy T Sato, JPJ Issa, P Kropf Cold Spring Harbor perspectives in medicine 7 (5), a026948, 2017 | 131 | 2017 |
| Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial G Garcia-Manero, G Roboz, K Walsh, H Kantarjian, E Ritchie, P Kropf, ... The Lancet Haematology 6 (6), e317-e327, 2019 | 93 | 2019 |
| Chronic myelogenous leukemia, version 1.2014 S O’Brien, JP Radich, CN Abboud, M Akhtari, JK Altman, E Berman, ... Journal of the National Comprehensive Cancer Network 11 (11), 1327-1340, 2013 | 85 | 2013 |
| Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia GJ Roboz, HM Kantarjian, KWL Yee, PL Kropf, CL O'Connell, EA Griffiths, ... Cancer 124 (2), 325-334, 2018 | 76 | 2018 |
| NCCN guidelines insights: chronic myeloid leukemia, version 1.2017 A Pallera, JK Altman, E Berman, CN Abboud, B Bhatnagar, P Curtin, ... Journal of the National Comprehensive Cancer Network 14 (12), 1505-1512, 2016 | 72 | 2016 |
| Chronic myelogenous leukemia, version 1.2015 S O’Brien, JP Radich, CN Abboud, M Akhtari, JK Altman, E Berman, ... Journal of the National Comprehensive Cancer Network 12 (11), 1590-1610, 2014 | 72 | 2014 |
| Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology R Mesa, C Jamieson, R Bhatia, MW Deininger, AT Gerds, I Gojo, J Gotlib, ... Journal of the National Comprehensive Cancer Network 14 (12), 1572-1611, 2016 | 71 | 2016 |
| Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia KA Foon, D Mehta, S Lentzsch, P Kropf, S Marks, D Lenzner, L Pietragallo, ... Blood, The Journal of the American Society of Hematology 119 (13), 3184-3185, 2012 | 67 | 2012 |
| Dasatinib promotes ATRA-induced differentiation of AML cells PL Kropf, L Wang, Y Zang, RL Redner, DE Johnson Leukemia 24 (3), 663-665, 2010 | 49 | 2010 |
| Splenic irradiation for splenomegaly: A systematic review NG Zaorsky, GR Williams, SK Barta, NF Esnaola, PL Kropf, SB Hayes, ... Cancer treatment reviews 53, 47-52, 2017 | 44 | 2017 |
| First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) HM Kantarjian, E Jabbour, K Yee, P Kropf, C O'Connell, W Stock, R Tibes, ... Blood, The Journal of the American Society of Hematology 122 (21), 497-497, 2013 | 40 | 2013 |
| Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms BL Stein, J Gotlib, M Arcasoy, MH Nguyen, N Shah, A Moliterno, ... Journal of the National Comprehensive Cancer Network 13 (4), 424-434, 2015 | 34 | 2015 |
| Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. C Fidler, T Klumpp, K Mangan, ME Martin, M Sharma, R Emmons, M Lu, ... American journal of hematology 87 (2), 219-221, 2011 | 26 | 2011 |
| Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia W Chung, AD Kelly, P Kropf, H Fung, J Jelinek, XY Su, GJ Roboz, ... Clinical epigenetics 11, 1-12, 2019 | 23 | 2019 |
| Chimeric antigen receptor T-cell therapy N Ogba, NM Arwood, NL Bartlett, M Bloom, P Brown, C Brown, EL Budde, ... Journal of the National Comprehensive Cancer Network 16 (9), 1092-1106, 2018 | 21 | 2018 |
| S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR … P Fenaux, M Gobbi, PL Kropf, J Mayer, GJ Roboz, H Döhner, J Krauter, ... HemaSphere 3, 394-395, 2019 | 19 | 2019 |
| Results from a Global Randomized Phase 3 Study of Guadecitabine (G) vs treatment choice (TC) in 815 patients with treatment naïve (TN) AML unfit for intensive chemotherapy (IC … GJ Roboz, H Döhner, M Gobbi, PL Kropf, J Mayer, J Krauter, T Robak, ... Blood 134, 2591, 2019 | 17 | 2019 |
